CN1114881A - Medicine containing multiple trace elements for neurasthenia - Google Patents
Medicine containing multiple trace elements for neurasthenia Download PDFInfo
- Publication number
- CN1114881A CN1114881A CN 94119241 CN94119241A CN1114881A CN 1114881 A CN1114881 A CN 1114881A CN 94119241 CN94119241 CN 94119241 CN 94119241 A CN94119241 A CN 94119241A CN 1114881 A CN1114881 A CN 1114881A
- Authority
- CN
- China
- Prior art keywords
- medicine
- neurasthenia
- trace elements
- starch
- sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The medicine for curing neurasthenia with 100% effective rate and 88% cure rate without any toxic by-effect is prepared from Cr2O3, phosphomolybdic acid, zinc sulfate and auxiliary material and contains more trace elements.
Description
The present invention relates to a kind of neurasthenic compound medicine of can treating of multiple eating trace element that contains, belong to field of medicaments.
In the existing tranquillizing and allaying excitement medicine commonly used both at home and abroad, still do not have a kind ofly not only can effect a radical cure, but also the high curative effect medicine of the neurasthenia of no dependence.
The objective of the invention is to overcome the dependency of tranquillizing and allaying excitement medicine in the past, be a kind of can conciliator's somatic nerves function the tranquillizing and allaying excitement medicine and without any toxic and side effects.
Trace element among the present invention is the ingredient of arginase, prolinase, pyruvate carboxylase, RNA polymerase, DNA-polymerase etc.Can activate carboxylase, phosphorylase, aldolase, phosphoglucomutase, Isocitrate dehydrogenase and cholinesterase.Form in vivo mucopolysaccharide, can with the material of protein bound, catalysis adenosine triphosphate, triphosphoric acid vernine, CTP and triphosphoric acid uridine aggregate into DNA (deoxyribonucleic acid).This medicine can promote proteinic synthetic, can also participate in neural information transmission.Magnesium, zinc, these cationes of manganese can form the equipotential electric charge with the phosphate group with negative electric charge, neuro hormone plays Stabilization to maincenter, suppress the hyperfunction and disturbance state of nervus centralis media in transmittance process, thereby eliminate the excessive excited phenomenon of cerebral nervous system, finally cure the neurasthenia.
The present invention contains the medicine of the neurasthenia of various trace elements and is made up of six kinds of edible inorganic salts, three kinds of vitamin and adjuvant, and its percentage by weight is as follows:
Chromic oxide: 0.005%-0.01%
Phosphomolybdic acid: 0.5%-1%
Zinc sulfate: 7.7%-12.6%
Ammonium molybdate: 16%-24%
Magnesium sulfate: 20.4%-31%
Manganese sulfate: 28%-36%
VB
1： 2％—3.1％
VB
2： 0.77％—1.24％
VB
6： 0.3％—0.7％
Starch: 6.2%-12.2%
Every kind of medicine in the said ratio is fully pulverized, dries, sieves, then itself and starch fully mixed, stirs, make granule, incapsulate and be this medicine.
Embodiment:
By above-mentioned manufacture method, its preferred plan of proportioning is:
Chromic oxide: 0.008%
Phosphorus aluminic acid: 0.8%
Zinc sulfate: 9.8%
Ammonium molybdate: 19.5%
Magnesium sulfate: 24.4%
Manganese sulfate: 32.5%
VB
1： 2.44％
VB
2： 0.98％
VB
6： 0.5％
Starch: 9.1%.
Medicine of the present invention has following advantage:
1, efficient: medicine of the present invention is nearly 100% to neurasthenia's effective percentage, cure rate 88%.Can remove patient's dreaminess insomnia, headache, dizzy, symptom, obviously memory reinforcing such as anxiety is fidgety.
2, have no side effect, this medicine composition is the trace element of needed by human, thereby drug safety is reliable, avirulence, without any side effects.
3, no Drug resistance, no dependence.
4, long action time, this product by replenish, trace element reaches balance in the control agent, thereby improve and eliminate neurasthenia symptom.This medicine slowly plays a role in human body, long action time.
Case 1: Xin Fuquan, the man, 33 years old, People's Armed Police cadre, main suit were often dizzy, dizzy, myasthenia of limbs even see that TV fears that insomnia can not be had a rest.More than 3 years, nineteen ninety was eaten above-mentioned medicine 40 days, one day three times, one time three, the symptom complete obiteration, energetic.
Case 2: Zhang Yongjiang, the man, 62 years old, the military region, Shanxi was stopped dried.Main suit's dizziness for over ten years, tinnitus, malaise, vexed, can only sleep 2-3 hours every day.Repeatedly hospitalization is invalid.After taking above-mentioned medicine in 1993, symptom complete obiteration, appetite, sleep be all fine.
Case 3: Guo Baolan, the woman, 37 years old, ill 5 years, often dizziness, tinnitus, headache, vexed usually can not be fallen asleep inappetence, general weakness whole night.Through tens families inside and outside the province large hospital fail to respond to any medical treatment.Take this medicine after tens days, symptom all disappears, and it is fine to see spirit, and appetite is good.
Claims (2)
1, a kind of by edible inorganic salt, the medicine of the neurasthenia that contains various trace elements that vitamin and adjuvant are formed is characterized in that described drug weight percentage ratio prescription is:
Chromic oxide: 0.005%-0.01%
Phosphomolybdic acid: 0.5%-1%
Zinc sulfate: 7.7%-12.6%
Ammonium molybdate: 16%-24%
Magnesium sulfate: 20.4%-31%
Manganese sulfate: 28%-36%
VB
1： 2％—3.1％
VB
2： 0.77％—1.24％
VB
6： 0.3％—0.7％
Starch: 6.2%-12.2%
Earlier every kind in said ratio medicine is fully pulverized, dries, sieved, medicine and starch after will pulverizing then fully mix, stir, and make granule, incapsulate to get final product.
2, the medicine that contains the neurasthenia of various trace elements according to claim 1 is characterized in that its best proportioning is
Chromic oxide: 0.008% phosphomolybdic acid: 0.8%
Zinc sulfate: 9.8% ammonium molybdate: 19.5%
Magnesium sulfate: 24.4% manganese sulfate: 32.5%
VB
1： 2.44％ VB2： 0.98％
VB
6: 0.5% starch: 9.1%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94119241A CN1062134C (en) | 1994-12-22 | 1994-12-22 | Medicine containing multiple trace elements for neurasthenia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94119241A CN1062134C (en) | 1994-12-22 | 1994-12-22 | Medicine containing multiple trace elements for neurasthenia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1114881A true CN1114881A (en) | 1996-01-17 |
| CN1062134C CN1062134C (en) | 2001-02-21 |
Family
ID=5039156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94119241A Expired - Fee Related CN1062134C (en) | 1994-12-22 | 1994-12-22 | Medicine containing multiple trace elements for neurasthenia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1062134C (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1077094A (en) * | 1992-09-30 | 1993-10-13 | 广西玉林地区亚热带保健饮料食品研究所 | Myrtaceae juice beverage and production method thereof |
| CN1080826A (en) * | 1993-01-07 | 1994-01-19 | 高泰兰 | Cap for calming nerves and strengthening brain and application method thereof |
-
1994
- 1994-12-22 CN CN94119241A patent/CN1062134C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1062134C (en) | 2001-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3240177C2 (en) | ||
| DE69229975T2 (en) | Pharmaceutical compositions containing an anticytokine | |
| DE69129331T2 (en) | USE OF INOSITE TRIPHOSPHATE FOR THE PREPARATION OF MEDICATIONS | |
| DE69414904T2 (en) | Pharmaceutical compositions containing silicate polymer | |
| DE69027540T2 (en) | USE OF INOSITOL PHOSPHATE FOR THE PRODUCTION OF A MEDICINAL PRODUCT | |
| DE60003837T2 (en) | TETRAPEPTIDE THAT STIMULATES THE FUNCTIONAL ACTIVITY OF NEURONES, THIS CONTAINING PHARMACOLOGICAL AGENT AND ITS USE | |
| ATE261721T1 (en) | SYSTEM FOR THE TARGETED DELIVERY OF ACTIVE INGREDIENTS, METHOD FOR ITS PRODUCTION AND USE | |
| DE69637104T2 (en) | REMEDIES FOR ARTHROSIS DEFORMANS AND INFLAMMATORY JOINT DISEASES | |
| DE68904507T2 (en) | USE OF INOSITOL TRIPHOSPHATE IN THE TREATMENT OF TISSUE DAMAGE. | |
| EP2207880A1 (en) | Catenate for immunostimulation | |
| CN1062134C (en) | Medicine containing multiple trace elements for neurasthenia | |
| DE69634905T2 (en) | Phosphnate analogues of mannose-6-phosphate and their use to promote the healing of wounds or fibrotic disorders with reduced scarring | |
| DE3830271A1 (en) | MEDIUM WITH IMMUNE SUPPRESSIVE EFFECT | |
| DE3421789C2 (en) | ||
| JPS60252416A (en) | Cdp choline composition | |
| EP2854823B1 (en) | Clay mineral for reducing inorganic phosphates, in particular in renal replacement therapy | |
| DE60203895T2 (en) | USE OF N-ACETYL-D-GLUCOSAMINE IN THE MANUFACTURE OF A MEDICAMENT FOR SUPPRESSING THE SIDE EFFECTS OF RADIOTHERAPY AND CHEMOTHERAPY | |
| DE2528460A1 (en) | 1-Carbamoyl 2-cyano aziridine as immunostimulant - for therapy of bacterial and viral infections | |
| DE3141970C2 (en) | ||
| DE3780157T2 (en) | USE OF 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDIN-3,5-DION AS AN ANTIVIRAL MEDICINE AGAINST AIDS. | |
| DE3840744C2 (en) | Activator for osteoblasts | |
| DE69914395T2 (en) | Dietary supplements | |
| CN1033207C (en) | Application of L-lysine hydrochloride in preparing medicine for treating craniocerebral trauma | |
| DE69901843T2 (en) | ONE OR MORE COMPONENTS OF MOTHER-OF-PEARL, INCLUDING BIO-ARAGONITE-CONTAINING HOMEOPATHIC MEDICINAL PRODUCT | |
| CN105193840A (en) | Kaolin suspension for treating chronic diarrhea and preparation method of kaolin suspension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |